The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data
Open accessAbstract
Background: A benchmark of near-perfect adherence (≥95%) to antiretroviral therapy (ART) is often cited as necessary for HIV viral suppression. However, given newer, more effective ART medications, the threshold for viral suppression may be lower. We estimated the minimum ART adherence level necessary to achieve viral suppression. Settings: The Patient-centered HIV Care Model demonstration project. Methods: Adherence to ART was calculated using the proportion of days covered measure for the 365-day period before each viral load test result, and grouped into 5 categories (<50%, 50% to <80%, 80% to <85%, 85% to <90%, and ≥90%). Binomial regression analyses were conducted to determine factors associated with viral suppression (HIV RNA <200 copies/mL); demographics, proportion of days covered category, and ART regimen type were explanatory variables. Generalized estimating equations with an exchangeable working correlation matrix accounted for correlation within subjects. In addition, probit regression models were used to estimate adherence levels required to achieve viral suppression in 90% of HIV viral load tests. Results: The adjusted odds of viral suppression did not differ between persons with an adherence level of 80% to <85% or 85% to <90% and those with an adherence level of ≥90%. In addition, the overall estimated adherence level necessary to achieve viral suppression in 90% of viral load tests was 82% and varied by regimen type; integrase inhibitor- and nonnucleoside reverse transcriptase inhibitor-based regimens achieved 90% viral suppression with adherence levels of 75% and 78%, respectively. Conclusions: The ART adherence level necessary to reach HIV viral suppression may be lower than previously thought and may be regimen-dependent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., Wagener, M. M., & Singh, N. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00004 · Cited by 3,289
Antiretroviral therapy for the prevention of HIV-1 transmission.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600693 · Cited by 1,700
Samji, H., Cescon, A., Hogg, R. S., Modur, S. P., Althoff, K. N., Buchacz, K., Burchell, A. N., Cohen, M., Gebo, K. A., Gill, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081355 · Cited by 1,417
Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., Bamberger, J. D., Chesney, M. A., & Moss, A. (2000) · AIDS · doi:10.1097/00002030-200003100-00008 · Cited by 1,033
May, M. T., Gompels, M., Delpech, V., Porter, K., Orkin, C., Kegg, S., Hay, P., Johnson, M., Palfreeman, A., Gilson, R., et al. (2014) · AIDS · doi:10.1097/qad.0000000000000243 · Cited by 593
Shubber, Z., Mills, E. J., Nachega, J. B., Vreeman, R., Freitas, M., Bock, P., Nsanzimana, S., Penazzato, M., Appolo, T., Doherty, M., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002183 · Cited by 526
Arnsten, J. H., Demas, P. A., Grant, R. W., Gourevitch, M. N., Farzadegan, H., Howard, A. A., & Schoenbaum, E. E. (2002) · Journal of General Internal Medicine · doi:10.1007/s11606-002-0044-3 · Cited by 501
Bangsberg, D. R., Acosta, E. P., Gupta, R., Guzman, D., Riley, E. D., Harrigan, P. R., Parkin, N., & Deeks, S. G. (2006) · AIDS · doi:10.1097/01.aids.0000199825.34241.49 · Cited by 312
Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis
Bezabhe, W. M., Chalmers, L., Bereznicki, L. R., & Peterson, G. M. (2016) · Medicine · doi:10.1097/md.0000000000003361 · Cited by 277
Levels of Adherence Required for Virologic Suppression Among Newer Antiretroviral Medications
Kobin, A. B., & Sheth, N. U. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p587 · Cited by 167
Cited by
Bogart, L. M., Ojikutu, B. O., Tyagi, K., Klein, D. J., Mutchler, M. G., Dong, L., Lawrence, S. J., Thomas, D. R., & Kellman, S. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002570 · Cited by 477
Pantalone, D. W., Nelson, K. M., Batchelder, A. W., Chiu, C., Gunn, H. A., & Horvath, K. J. (2020) · The Journal of Sex Research · doi:10.1080/00224499.2020.1728514 · Cited by 81
“…category has been an especially prolific area of behavioral intervention research, given the high levels of medication adherence needed to maintain virologic control (>75% of prescribed doses, depending on regimen; Byrd et al., 2019) and the indefinite treatment duration (Günthard et al., 2016).”
BackgroundDreyer, A. J., Nightingale, S., Andersen, L. S., Lee, J. S., Gouse, H., Safren, S. A., O’Cleirigh, C., Thomas, K. G. F., & Joska, J. (2023) · AIDS and Behavior · doi:10.1007/s10461-023-03992-7 · Cited by 3
Metadata
- Authors
- Byrd, K. K., Hou, J. G., Hazen, R., Kirkham, H., Suzuki, S., Clay, P. G., Bush, T., Camp, N. M., Weidle, P. J., Delpino, A., & for the Patient-Centered HIV Care Model Team
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2019-11-01
- Volume
- 82
- Issue
- 3
- Pages
- 245-251
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W2962926112
- Cited by
- 285
- References
- 27
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data. https://app.cochat.ai/papers/10.1097/qai.0000000000002142
- The paper
- Byrd, K. K., Hou, J. G., Hazen, R., Kirkham, H., Suzuki, S., Clay, P. G., Bush, T., Camp, N. M., Weidle, P. J., Delpino, A., & for the Patient-Centered HIV Care Model Team. (2019). Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/qai.0000000000002142
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.